StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 06:41:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032 http://www.streetinsider.com/Corporate+News/Precigen+receives+FDA+orphan+drug+exclusivity+for+PAPZIMEOS+through+2032/26643942.html <p>Precigen Inc. (NASDAQ: PGEN) received orphan drug exclusivity from the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis (RRP), extending market protection through August 2032.</p><p>The exclusivity prevents FDA approval of similar drugs for RRP for seven years. RRP is a rare respiratory disease affecting fewer than 200,000 people in the United States, where patients typically undergo multiple surgeries annually to remove benign tumors in the respiratory tract.</p><p>PAPZIMEOS uses a modified adenovirus to train the immune system to target proteins in HPV 6 and HPV 11, which cause RRP. The drug is currently available commercially in the United States and http://www.streetinsider.com/Corporate+News/Precigen+receives+FDA+orphan+drug+exclusivity+for+PAPZIMEOS+through+2032/26643942.html Mon, 15 Jun 2026 06:41:39 -0400 PGEN Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032 http://www.streetinsider.com/FDA/Precigen+receives+FDA+orphan+drug+exclusivity+for+PAPZIMEOS+through+2032/26643942.html <p>Precigen Inc. (NASDAQ: PGEN) received orphan drug exclusivity from the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis (RRP), extending market protection through August 2032.</p><p>The exclusivity prevents FDA approval of similar drugs for RRP for seven years. RRP is a rare respiratory disease affecting fewer than 200,000 people in the United States, where patients typically undergo multiple surgeries annually to remove benign tumors in the respiratory tract.</p><p>PAPZIMEOS uses a modified adenovirus to train the immune system to target proteins in HPV 6 and HPV 11, which cause RRP. The drug is currently available commercially in the United States and http://www.streetinsider.com/FDA/Precigen+receives+FDA+orphan+drug+exclusivity+for+PAPZIMEOS+through+2032/26643942.html Mon, 15 Jun 2026 06:41:39 -0400 PGEN Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging http://www.streetinsider.com/Press+Releases/Precigen+Gains+Advantage+as+PAPZIMEOS+Granted+Orphan+Drug+Exclusivity+by+FDA%3B+Long-Term+Data+From+Clinical+Study+Encouraging/26643941.html <p><i><strong>Meg Flippin, Benzinga Staff Writer</strong></i></p><p><i><strong>Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease</strong></i></p> <p><strong id="dateline">GERMANTOWN, MD / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 15, 2026 / </strong><strong>Precigen Inc. </strong>(NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract.</p><a href="https://app.accessnewswire.com/imagelibrary/ba627f92-c161-4878-98bb-ab8347d57b91/1177080/precigen-061426.jpg" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/ba627f92-c161-4878-98bb-ab8347d57b91/1177080/precigen-061426.jpg" style="width:715px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div><p>The commercial-stage precision medicines company was just granted orphan drug exclusivity by the http://www.streetinsider.com/Press+Releases/Precigen+Gains+Advantage+as+PAPZIMEOS+Granted+Orphan+Drug+Exclusivity+by+FDA%3B+Long-Term+Data+From+Clinical+Study+Encouraging/26643941.html Mon, 15 Jun 2026 06:40:00 -0400 PGEN Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging http://www.streetinsider.com/ACCESS+Newswire/Precigen+Gains+Advantage+as+PAPZIMEOS+Granted+Orphan+Drug+Exclusivity+by+FDA%3B+Long-Term+Data+From+Clinical+Study+Encouraging/26643941.html <p><i><strong>Meg Flippin, Benzinga Staff Writer</strong></i></p><p><i><strong>Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease</strong></i></p> <p><strong id="dateline">GERMANTOWN, MD / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 15, 2026 / </strong><strong>Precigen Inc. </strong>(NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract.</p><a href="https://app.accessnewswire.com/imagelibrary/ba627f92-c161-4878-98bb-ab8347d57b91/1177080/precigen-061426.jpg" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/ba627f92-c161-4878-98bb-ab8347d57b91/1177080/precigen-061426.jpg" style="width:715px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div><p>The commercial-stage precision medicines company was just granted orphan drug exclusivity by the http://www.streetinsider.com/ACCESS+Newswire/Precigen+Gains+Advantage+as+PAPZIMEOS+Granted+Orphan+Drug+Exclusivity+by+FDA%3B+Long-Term+Data+From+Clinical+Study+Encouraging/26643941.html Mon, 15 Jun 2026 06:40:00 -0400 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/Press+Releases/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html <div class="xn-content"> <ul type="disc"><li><i>Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location> and <location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4708950-1&h=1374259457&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></span></a><span> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the <span>Recurrent Respiratory Papillomatosis Foundation</span> (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.</span></p> http://www.streetinsider.com/PRNewswire/Precigen+and+the+Recurrent+Respiratory+Papillomatosis+Foundation+Recognize+International+RRP+Awareness+Day+by+Elevating+Patient+and+Community+Voices/26632799.html Thu, 11 Jun 2026 08:00:00 -0400 A.06822034 O.13607936 O.20026344 PGEN H.C. Wainwright Reiterates Buy Rating on Precigen Inc. (PGEN) http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Precigen+Inc.+%28PGEN%29/26587096.html <p>H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $14.00 price target on Precigen Inc. (NASDAQ: PGEN).</p><p>The analyst commented: "On May 30, 2026, at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO), Precigen presented mature follow-up data from the pivotal trial with PAPZIMEOS (zopapogene imadenovec-drba) that evaluated the drug as a therapy for recurrent respiratory papillomatosis (RRP). As of the April 30, 2026 assessment, 15 of 18 complete responders (83%) remained in complete response and had received no further RRP treatment of any kind during the follow-up period, be it surgery or off-label investigational agents. http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Precigen+Inc.+%28PGEN%29/26587096.html Tue, 02 Jun 2026 06:57:07 -0400 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Tennant Phil http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html si-local-file:///var/storage/secattach/20260601/26584153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Tennant Phil http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html si-local-file:///var/storage/secattach/20260601/26584153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Tennant+Phil/26584153.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Thomasian Harry Jr. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html si-local-file:///var/storage/secattach/20260601/26584166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Thomasian Harry Jr. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html si-local-file:///var/storage/secattach/20260601/26584166.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Thomasian+Harry+Jr./26584166.html Mon, 01 Jun 2026 16:29:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Lehr Donald P. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html si-local-file:///var/storage/secattach/20260601/26584120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Lehr Donald P. http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html si-local-file:///var/storage/secattach/20260601/26584120.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Lehr+Donald+P./26584120.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Shah Rutul R http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html si-local-file:///var/storage/secattach/20260601/26584130.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Shah Rutul R http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html si-local-file:///var/storage/secattach/20260601/26584130.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Shah+Rutul+R/26584130.html Mon, 01 Jun 2026 16:27:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Sabzevari Helen http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html si-local-file:///var/storage/secattach/20260601/26584099.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html Mon, 01 Jun 2026 16:26:00 -0400 O.13607936 PGEN Form 4 PRECIGEN, INC. For: May 28 Filed by: Sabzevari Helen http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html si-local-file:///var/storage/secattach/20260601/26584099.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PRECIGEN%2C+INC.++++++++++++For%3A+May+28++Filed+by%3A+Sabzevari+Helen/26584099.html Mon, 01 Jun 2026 16:26:00 -0400 O.13607936 PGEN Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700195-1&h=1290708377&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html <div class="xn-content"> <ul type="disc"><li><i><span>15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP</span></i></li><li><i><span>5 complete responders have ongoing responses beyond 4 years</span></i></li><li><i><span>Follow-up is ongoing; median duration of complete response has not yet been reached</span></i></li><li><i><span>No new adverse safety events have been observed during long-term follow-up</span></i></li><li><i><span><span value="ACORN:0682203466" idsrc="xmltag.org" >US FDA</span> granted seven-year period of orphan drug market exclusivity to PAPZIMEOS</span></i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gerown" idsrc="xmltag.org" >GERMANTOWN, Md.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span><a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4700195-1&h=1290708377&u=https%3A%2F%2Fprecigen.com%2F&a=Precigen%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PGEN" idsrc="xmltag.org" >Precigen, Inc.</span></a> (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of http://www.streetinsider.com/Press+Releases/Precigen+Presents+New+Long-Term+Durability+Data+for+PAPZIMEOS%2C+Recently+Granted+Seven-Year+Market+Exclusivity%2C+Demonstrating+Complete+Responses+Beyond+4+Years/26577264.html Sat, 30 May 2026 14:30:00 -0400 A.06822034 A.50216726 O.13607936 O.20026344 O.21612337 PGEN